Skip to main content

Vincent Kazmer, Eric Neumann, Michael Lytton, Gerhard Laur, Stefan Ryser


Vincent Kazmer, formerly executive vice president and chief financial officer of NetGenics, has joined Phase-1 Molecular Toxicology of Santa Fe, N.M., as chief executive officer.

Prior to NetGenics, Kazmer was president, chief executive officer, and director of Lark Technologies, a molecular biology contract research organization; a co-founder and president of Copernicus Gene Systems Inc., a private gene therapy company; senior vice president of United States Biochemical; and a co-founder and vice president of Ribozyme Pharmaceuticals.

Eric Neumann has resigned from his post as vice president of life science informatics at 3rd Millennium of Cambridge, Mass. He will remain in the Boston area where he will work as an independent consultant.

Genaissance Pharmaceuticals of New Haven, Conn., has appointed Michael Lytton, general partner at Oxford Bioscience Partners, to its board of directors. Gerhard Laur, head of merchant banking at A&A Actienbank and Stefan Ryser, managing director of Bear Stearns Health Innoventures, are leaving the board, which now numbers seven.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.